# US 6,727,278 B1 · Pharmaceutically active agents that impede amyloid formation in vivo

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,278 B1
- Document ID: US6727278B1
- Status: Granted
- Kind: B1
- Application number: 08/482,768
- Filed: 1995-06-07
- Granted: 2004-04-27
- Earliest claimed: 1986-08-27
- Assignees: DMS Pharmaceutical Inc.
- Inventors: Paul Averback
- Web page: https://patentgrep.com/patent/US6727278B1

## CPC

- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- A61K 31/35: having six-membered rings with one oxygen as the only ring hetero atom
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/42: Oxazoles
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/63: Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K 31/655: Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
- A61K 31/70: Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047)
- C07H 17/08: Hetero rings containing eight or more ring members, e.g. erythromycins
- C07H 19/06: Pyrimidine radicals
- G01N 33/5088: {of vertebrates}
- G01N 2333/4709: Amyloid plaque core protein
- G01N 2500/00: Screening for compounds of potential therapeutic value
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)

## Abstract

Dense microspheres can be extracted and purified to substantial homogeneity from mammalian brain tissue, and used in the screening of therapies for potential effectiveness in impeding the formation of amyloid fibrils associated with Alzheimer's disease and other forms of cerebral amyloidosis. Compounds that, at in-tissue concentrations of 10−5 M or less, inhibit amyloid formation in a test animal injected intracerebrally with dense microspheres are particularly useful in inhibiting treating cerebral amyloidosis.

## Claims

### Claim 1

A composition comprising (a) an amyloid fibril inhibitory effective amount of a compound that inhibits formation of amyloid fibrils when administered, at an in-tissue concentration of about 10−5 or less, to a test animal that has received an intracerebral injection of DMS wherein said compound is selected from the group consisting of pyrimethamin, cromolyn sodium, erythyromycin, purpurogallin, tartrazine, sulfanilamide, benzopurpurine, benzopurpurine 4B, 29H, 31H-phthalocyanine, 5-methyl-2-thiouridine and 1,2-benzylsoxazole and (b) a pharmaceutically acceptable carrier, wherein said composition is capable of crossing the blood-brain barrier.

### Claim 2 (depends on 1)

The composition as claimed in claim 1, wherein said compound inhibits formation of amyloid fibrils by acting on DMS components such that a structural transition of DMS protein in the brain to a β-pleated sheet conformation is prevented.

### Claim 3 (depends on 1)

A composition as claimed in claim 1, wherein said pharmaceutically acceptable carrier is a physiological saline solution.

### Claim 4 (depends on 1)

A composition as claimed in claim 1, wherein said composition is orally acceptable.

### Claim 5 (depends on 1)

A composition as claimed in claim 1, wherein said composition is rectally acceptable.

### Claim 6 (depends on 1)

A composition as claimed in claim 1, wherein said composition is nasally acceptable.

### Claim 7 (depends on 6)

A composition as claimed in claim 6, wherein said composition is in spray or aerosol form.
